Cartography Biosciences, a biotech developing T-cell engaging bispecific and multispecific antibody therapeutics for cancer, closed a $67 million Series B financing led by Pfizer Ventures. The funding aims to accelerate clinical development of its lead colorectal cancer program targeting novel antigens. This financing is expected to bolster Cartography's transition from collaborative efforts—including a recent partnership with Gilead—to independently advancing its pipeline, reflecting strong investor confidence. The company focuses on differentiated immuno-oncology modalities addressing unmet needs in hard-to-treat tumors.